Alnylam Pharmaceuticals, Inc.

NasdaqGS:ALNY Stock Report

Market Cap: US$58.8b

Alnylam Pharmaceuticals Future Growth

Future criteria checks 6/6

Alnylam Pharmaceuticals is forecast to grow earnings and revenue by 54.1% and 25.8% per annum respectively. EPS is expected to grow by 54.6% per annum. Return on equity is forecast to be 49% in 3 years.

Key information

54.1%

Earnings growth rate

54.59%

EPS growth rate

Biotechs earnings growth25.5%
Revenue growth rate25.8%
Future return on equity49.02%
Analyst coverage

Good

Last updated08 Aug 2025

Recent future growth updates

Recent updates

Need To Know: Analysts Are Much More Bullish On Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Aug 01
Need To Know: Analysts Are Much More Bullish On Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Alnylam: Amvuttra Is Just Getting Started

Jul 31

We Take A Look At Why Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) CEO Has Earned Their Pay Packet

May 01
We Take A Look At Why Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) CEO Has Earned Their Pay Packet

Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster

Mar 21

Alnylam: Waiting For Regulatory Updates In March

Feb 13

Is Alnylam Pharmaceuticals (NASDAQ:ALNY) A Risky Investment?

Jan 17
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) A Risky Investment?

What Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) P/S Is Not Telling You

Dec 16
What Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) P/S Is Not Telling You

Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch

Oct 27

Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?

Sep 12
Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?

Alnylam: HELIOS-B Success Priced In Already

Aug 30

RNAi: Winning In The Clinic, Now For The Market

Jun 25

Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation

Jun 03

Is Alnylam's HELIOS-B Delay A Red Flag?

Mar 10

Alnylam's Huge Opportunity

Jan 12

Earnings and Revenue Growth Forecasts

NasdaqGS:ALNY - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20276,2641,5461,8342,32323
12/31/20264,8307411,2411,11129
12/31/20253,50212942128228
6/30/20252,462-319-52-16N/A
3/31/20252,348-270-75-45N/A
12/31/20242,248-278-43-8N/A
9/30/20242,095-3321657N/A
6/30/20242,344-73319372N/A
3/31/20242,003-332128189N/A
12/31/20231,828-44042104N/A
9/30/20231,724-510-672N/A
6/30/20231,237-1,064-541-473N/A
3/31/20231,143-1,065-605-537N/A
12/31/20221,037-1,131-613-541N/A
9/30/2022961-1,182-632-559N/A
6/30/2022884-981-660-578N/A
3/31/2022880-893-654-577N/A
12/31/2021844-853-718-642N/A
9/30/2021749-838-691-615N/A
6/30/2021688-887-653-591N/A
3/31/2021571-876-672-604N/A
12/31/2020493-858-685-615N/A
9/30/2020401-891-775-688N/A
6/30/2020345-846-871-760N/A
3/31/2020286-886-452-336N/A
12/31/2019220-886-419-278N/A
9/30/2019169-821-372-233N/A
6/30/2019101-858-352-204N/A
3/31/201986-802N/A-595N/A
12/31/201875-761N/A-563N/A
9/30/201892-692N/A-515N/A
6/30/2018107-570N/A-460N/A
3/31/201893-525N/A-438N/A
12/31/201790-491N/A-383N/A
9/30/201769-462N/A-358N/A
6/30/201766-443N/A-335N/A
3/31/201759-414N/A-324N/A
12/31/201647-410N/A-308N/A
9/30/201637-388N/A-282N/A
6/30/201630-361N/A-261N/A
3/31/201630-342N/A-247N/A
12/31/201541-290N/A-189N/A
9/30/201558-221N/A-173N/A
6/30/201562-188N/A-159N/A
3/31/201561-160N/A-150N/A
12/31/201451-360N/A-166N/A
9/30/201437-371N/A-151N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALNY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.1%).

Earnings vs Market: ALNY is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ALNY is expected to become profitable in the next 3 years.

Revenue vs Market: ALNY's revenue (25.8% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: ALNY's revenue (25.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ALNY's Return on Equity is forecast to be very high in 3 years time (49%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/18 18:32
End of Day Share Price 2025/08/18 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alnylam Pharmaceuticals, Inc. is covered by 67 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Huidong WangBarclays
Emily BodnarBerenberg